Literature DB >> 17448566

Altered expression of TLR homolog RP105 on monocytes hypersensitive to LPS in patients with primary biliary cirrhosis.

Yutaka Honda1, Satoshi Yamagiwa, Yasunobu Matsuda, Masaaki Takamura, Takafumi Ichida, Yutaka Aoyagi.   

Abstract

BACKGROUNDS/AIMS: Toll-like receptors (TLRs) have emerged as a key component of the innate immune system that triggers antimicrobial responses. Altered monocyte responses to ligands for TLRs have been reported in patients with primary biliary cirrhosis (PBC), yet the precise mechanism remains unknown.
METHODS: We investigated in vitro responses to a TLR4 ligand, lipopolysaccharide (LPS), using peripheral blood mononuclear cells and monocytes from 25 patients with PBC, 10 patients with chronic viral hepatitis (CVH), and 20 healthy individuals.
RESULTS: After stimulation with LPS, we found significantly higher amounts of IL-1beta, IL-6, and IL-8 production in PBC patients. Through the TLR4 signaling pathway, activation of NF-kappaB and expression of MyD88 mRNA were significantly increased in PBC patients, and the level of TLR4 expression was significantly increased on PBC monocytes as compared with CVH patients and controls. Of significance, the surface expression of RP105, which has recently been shown to be involved in negative regulation of TLR4 signaling, on PBC monocytes was significantly decreased in comparison with CVH patients (P=0.016) and controls (P<0.001).
CONCLUSIONS: These results suggest that expression of RP105 and TLR4 is altered on PBC monocytes, which appear to be hypersensitive to LPS, resulting in increased secretion of pro-inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448566     DOI: 10.1016/j.jhep.2007.03.012

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

Review 1.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

Review 2.  Role of autoimmunity in primary biliary cirrhosis.

Authors:  Tian-Yan Shi; Feng-Chun Zhang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

3.  Toll-like receptors as targets in chronic liver diseases.

Authors:  A Mencin; J Kluwe; R F Schwabe
Journal:  Gut       Date:  2009-05       Impact factor: 23.059

4.  High levels of FCγR3A and PRF1 expression in peripheral blood mononuclear cells from patients with primary biliary cirrhosis.

Authors:  Shan Li; Danxu Ma; Lei Zhang; Xi Li; Chuiwen Deng; Xue Qin; Ting Zhang; Li Wang; Qun Shi; Qian Wang; Qingjun Wu; Xuan Zhang; Fengchun Zhang; Yongzhe Li
Journal:  Dig Dis Sci       Date:  2012-11-23       Impact factor: 3.199

Review 5.  Macrophages and the Recovery from Acute and Chronic Inflammation.

Authors:  Kajal Hamidzadeh; Stephen M Christensen; Elizabeth Dalby; Prabha Chandrasekaran; David M Mosser
Journal:  Annu Rev Physiol       Date:  2016-12-07       Impact factor: 19.318

6.  Interaction between periodontitis and liver diseases.

Authors:  Pengyu Han; Dianxing Sun; Jie Yang
Journal:  Biomed Rep       Date:  2016-07-18

Review 7.  Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

Review 8.  Toll-like receptors in pathophysiology of liver diseases.

Authors:  Safak Kiziltas
Journal:  World J Hepatol       Date:  2016-11-18

Review 9.  The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review.

Authors:  Wen-Tao Ma; Fei Gao; Kui Gu; De-Kun Chen
Journal:  Front Immunol       Date:  2019-05-24       Impact factor: 7.561

10.  The role of vitamin d in primary biliary cirrhosis: possible genetic and cell signaling mechanisms.

Authors:  Khanh Vinh Quốc L Ng; Lan Thi Hoàng Nguyễn
Journal:  Gastroenterol Res Pract       Date:  2013-03-26       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.